# CGB-400 for the Reduction of Facial Redness

> **NCT04508660** · PHASE1 · COMPLETED · sponsor: **CAGE Bio Inc.** · enrollment: 25 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** CGB-400

## Key facts

- **NCT ID:** NCT04508660
- **Lead sponsor:** CAGE Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-26
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-04-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508660, "CGB-400 for the Reduction of Facial Redness". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04508660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*